Biogen (BIIB)
(Delayed Data from NSDQ)
$185.68 USD
+0.90 (0.49%)
Updated Oct 4, 2024 04:00 PM ET
Pre-Market: $185.50 -0.18 (-0.10%) 9:26 AM ET
3-Hold of 5 3
B Value D Growth B Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$185.68 USD
+0.90 (0.49%)
Updated Oct 4, 2024 04:00 PM ET
Pre-Market: $185.50 -0.18 (-0.10%) 9:26 AM ET
3-Hold of 5 3
B Value D Growth B Momentum B VGM
Zacks News
Medtronic (MDT) Q4 Earnings Miss Estimates, Revenues Beat
by Zacks.com
Medtronic (MDT) demonstrates weak fiscal fourth-quarter performances at CER, attributable to dismal show in all major business segments and geographies.
McKesson (MCK) Q4 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
McKesson's (MCK) fiscal fourth-quarter 2020 results benefit from strong segmental performance.
Zacks.com featured highlights include: Graphic Packaging, Canadian Solar, Biogen and Vistra Energy
by Zacks Equity Research
Zacks.com featured highlights include: Graphic Packaging, Canadian Solar, Biogen and Vistra Energy
Coronavirus Ruining Portfolio? Bet on These 4 Low P/CF Stocks
by Sumit Singh
Investment in stocks made on diligent value analysis is usually considered one of the best practices. In value investing, investors pick stocks that are cheap but fundamentally sound.
Novartis Gets EC Approval for Gene Therapy Zolgensma in SMA
by Zacks Equity Research
Novartis' (NVS) gene therapy, Zolgensma, obtains EC approval for spinal muscular atrophy.
4 Low Price-to-Book Value Stocks to Buy in May
by Kinjel Shah
Though price-to-earnings and price-to-sales are the first choices, P/B ratio is also a convenient tool for identifying valuable stocks.
STERIS' (STE) Q4 Earnings Surpass Estimates, Margins Rise
by Zacks Equity Research
STERIS' (STE) fourth-quarter fiscal 2020 results reflect strong segmental performance despite the coronavirus-led economic crisis.
GNC Holdings' (GNC) Q1 Earnings and Sales Miss Estimates
by Zacks Equity Research
All the operating segments of GNC Holdings (GNC) register significant year-over-year sales decline in Q1 on coronavirus-led business disruption.
AMN Healthcare (AMN) Q1 Earnings In Line With Estimates
by Zacks Equity Research
AMN Healthcare (AMN) gained from core operating segments in Q1.
Sanofi's Blood Disorder Candidate Gets FDA's Priority Review
by Zacks Equity Research
The FDA grants priority review to Sanofi's (SNY) regulatory application for sutimlimab for the treatment of hemolysis in adult patients with cold agglutinin disease (CAD).
Intersect ENT (XENT) Reports Wider-Than-Expected Q1 Loss
by Zacks Equity Research
Intersect ENT (XENT) performs disappointingly in the first quarter of 2020 due to the coronavirus crisis.
Phibro (PAHC) Q3 Earnings Surpass Estimates, Margin Declines
by Zacks Equity Research
Phibro (PAHC) witnessed revenue uptick in its core Animal Health segment in Q3 despite the coronavirus-led business disruptions in the animal production industry.
HMS Holdings (HMSY) Earnings and Revenues Beat Estimates in Q1
by Zacks Equity Research
HMS Holdings (HMSY) witnessed revenue growth at COB and PI segments in Q1.
Allscripts (MDRX) Q1 Earnings and Revenues Miss Estimates
by Zacks Equity Research
Allscripts (MDRX) witnessed a decline in core Client Services and Software delivery unit revenues in Q1.
National Vision (EYE) Q1 Earnings Top Estimates, Margin Falls
by Zacks Equity Research
National Vision's (EYE) first-quarter 2020 results were better than expected despite the coronavirus-led economic crisis.
Integer Holdings (ITGR) Q1 Earnings & Revenues Top Estimates
by Zacks Equity Research
Integer Holdings' (ITGR) first-quarter results benefit from strength in Cardio & Vascular sub-segment and margin expansion.
Zimmer Biomet (ZBH) Q1 Earnings Top, Revenues Miss Estimates
by Zacks Equity Research
The spread of coronavirus results in deferral of elective procedures for Zimmer Biomet (ZBH) in Q1.
Insulet (PODD) Q1 Earnings Lag Estimates, Margins Decline
by Zacks Equity Research
Insulet's (PODD) first-quarter 2020 results reflect mixed segmental performance amid the coronavirus-led economic crisis.
Fresenius Medical (FMS) Q1 Earnings Miss Estimates, Fall Y/Y
by Zacks Equity Research
Fresenius Medical's (FMS) first-quarter earnings benefit from strong segmental performance.
Cardinal Health (CAH) Beats Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Cardinal Health's (CAH) fiscal third-quarter results benefit from strong segmental performance.
LHC Group (LHCG) Earnings and Revenues Beat Estimates in Q1
by Zacks Equity Research
LHC Group (LHCG) continues to gain from home health services and hospice admissions, which improved year over year in Q1.
Are Biotech ETFs in Trouble as Coronavirus Dims Guidance?
by Sweta Jaiswal, FRM
Let's take a look at some ETFs with exposure to major players in the U.S. biotech industry, post their Q1 earnings releases amid the coronavirus crisis.
OPKO Health (OPK) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
OPKO Health's (OPK) first-quarter results benefit from increase in RAYALDEE prescriptions.
Globus Medical (GMED) Misses on Q1 Earnings and Revenues
by Zacks Equity Research
Globus Medical (GMED) witnesses around $20 million of COVID-19 related adverse impact on its Q1 sales.
Omnicell (OMCL) Q1 Earnings Top, Operating Margin Rises
by Zacks Equity Research
Omnicell's (OMCL) Q1 revenues suffer due to slowdown in hospital purchasing decisions and product bookings.